BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nanjing Leads Biolabs Co.\,Ltd readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Nanjing Leads Biolabs Co.\,Ltd's 
 drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05170958-2588@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Opamtistomig: Phase 1/2 readout est. (NCT05170958)
DESCRIPTION:Opamtistomig\, phase 1/2.\nStudy: A Phase I/II Clinical Study o
 f LBL-024 in Patients With Advanced Malignant Tumors\nEstimated primary co
 mpletion: December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/opamtistomig#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05170958
URL:https://assetmemo.bio/drug/opamtistomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06783647-2588@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Opamtistomig: Phase 2 readout est. (NCT06783647)
DESCRIPTION:Opamtistomig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid
  Tumours[Substudy 01(NSCLC)]\nEstimated primary completion: 24 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/opamtistomig#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06783647
URL:https://assetmemo.bio/drug/opamtistomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06157827-2588@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Opamtistomig: Phase 1/2 readout est. (NCT06157827)
DESCRIPTION:Opamtistomig\, phase 1/2.\nStudy: A Clinical Trial of LBL-024 C
 ombined With Etoposide and Platinum in Patients With Advanced Neuroendocri
 ne Carcinoma\nEstimated primary completion: 28 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/opamtistomig#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06157827
URL:https://assetmemo.bio/drug/opamtistomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07099430-2588@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Opamtistomig: Phase 1/2 readout est. (NCT07099430)
DESCRIPTION:Opamtistomig\, phase 1/2.\nStudy: A Trial of LBL-024 Monotherap
 y or Combination With Toripalimab in Patients With Advanced Melanoma.\nEst
 imated primary completion: 30 October 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/opamtistomig#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07099430
URL:https://assetmemo.bio/drug/opamtistomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07042802-2588@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20271225
DTEND;VALUE=DATE:20271226
SUMMARY:Opamtistomig: Phase 1/2 readout est. (NCT07042802)
DESCRIPTION:Opamtistomig\, phase 1/2.\nStudy: A Study of LBL-024 in Combina
 tion With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistan
 t Ovarian Cancer\nEstimated primary completion: 25 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/opamtistomig#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07042802
URL:https://assetmemo.bio/drug/opamtistomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111546-2588@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20271226
DTEND;VALUE=DATE:20271227
SUMMARY:Opamtistomig: Phase 2 readout est. (NCT07111546)
DESCRIPTION:Opamtistomig\, phase 2.\nStudy: A Clinical Trial of LBL-024 Com
 bination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)
 ]\nEstimated primary completion: 26 December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/opamtistomig#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07111546
URL:https://assetmemo.bio/drug/opamtistomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281976-2588@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Opamtistomig: Phase 1/2 readout est. (NCT07281976)
DESCRIPTION:Opamtistomig\, phase 1/2.\nStudy: A Trial of LBL-024 Monotherap
 y or Combination Drug in Patients With Triple Negative Breast Cancer\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/opamtistomig#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07281976
URL:https://assetmemo.bio/drug/opamtistomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07390383-2588@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Opamtistomig: Phase 2 readout est. (NCT07390383)
DESCRIPTION:Opamtistomig\, phase 2.\nStudy: A Phase II Clinical Trial of LB
 L-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
 \nEstimated primary completion: 30 May 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/opamtistomig#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07390383
URL:https://assetmemo.bio/drug/opamtistomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07331155-2588@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20281226
DTEND;VALUE=DATE:20281227
SUMMARY:Opamtistomig: Phase 2 readout est. (NCT07331155)
DESCRIPTION:Opamtistomig\, phase 2.\nStudy: A Phase II Clinical Study of LB
 L-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 
 03(ESCC)]\nEstimated primary completion: 26 December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/opamtistomig#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07331155
URL:https://assetmemo.bio/drug/opamtistomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06049290-3140@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20290920
DTEND;VALUE=DATE:20290921
SUMMARY:LBL-034: Phase 1/2 readout est. (NCT06049290)
DESCRIPTION:LBL-034\, phase 1/2\, Multiple Myeloma.\nStudy: A Clinical Tria
 l of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma\nEstima
 ted primary completion: 20 September 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/lbl-034#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06049290
URL:https://assetmemo.bio/drug/lbl-034#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791758-2588@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20300904
DTEND;VALUE=DATE:20300905
SUMMARY:Opamtistomig: Phase 1/2 readout est. (NCT07791758)
DESCRIPTION:Opamtistomig\, phase 1/2.\nStudy: A Clinical Trial of LBL-024 C
 ombination Drug in Patients With Metastatic Colorectal Carcinoma\nEstimate
 d primary completion: 4 September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/opamtistomig#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07791758
URL:https://assetmemo.bio/drug/opamtistomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720193-2588@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20301222
DTEND;VALUE=DATE:20301223
SUMMARY:Opamtistomig: Phase 3 readout est. (NCT07720193)
DESCRIPTION:Opamtistomig\, phase 3.\nStudy: A Trial of LBL-024 Combined Wit
 h Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC\nEstima
 ted primary completion: 22 December 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/opamtistomig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07720193
URL:https://assetmemo.bio/drug/opamtistomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
